LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.01

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$219.79M
EPS-2.8500
P/E Ratio-2.46
Earnings Date07/29/2026

lenz

Total Payables

Last Annual Value

4.17M

3-Year CAGR

-7%

5-Year CAGR

46%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Total Payables

LENZ · NASDAQ
CompanyTotal Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
4.17M
-10.0%55.4%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
5.76M
18.0%31.9%26.8%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
5.81M
21.1%41.2%14.5%
5.72M
95.8%25.9%N/A
1.17M
-28.6%-18.1%-9.6%
11.26M
22.3%11.0%47.9%
0.00
N/AN/AN/A
1.18M
-36.8%14.5%N/A
8.89M
-23.1%44.0%N/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.01, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.01